Calculated Under Revenue Guidance In Effect Before Topic 606 was Medifast’s largest revenue line in fiscal 2018, bringing in $499.20M of $501.00M (100%).
| Initial Application Period Cumulative Effect Transition | FY 2018 |
|---|---|
| Calculated Under Revenue Guidance In Effect Before Topic 606 | $499.20M |
| Difference Between Revenue Guidance In Effect Before & After Topic 606 | $1.81M |
| Total | $501.00M |
Medifast brought in $501.00M from its two revenue lines in fiscal 2018, the year ended December 31, 2018. Calculated Under Revenue Guidance In Effect Before Topic 606 was the largest at $499.20M (99.6%), ahead of Difference Between Revenue Guidance In Effect Before & After Topic 606 at $1.81M (0.4%).
Medifast (MED) reports its revenue by initial application period cumulative effect transition. In fiscal 2018, Calculated Under Revenue Guidance In Effect Before Topic 606 was its largest revenue line, bringing in $499.20M (99.6% of the total), followed by Difference Between Revenue Guidance In Effect Before & After Topic 606 at $1.81M (0.4%).
Calculated Under Revenue Guidance In Effect Before Topic 606 was Medifast's largest revenue line in fiscal 2018, bringing in $499.20M, or 99.6% of the $501.00M total across its two revenue lines.
Every figure comes from Medifast's annual financial filings, as reported. Each line keeps the name Medifast gives it, and years follow its fiscal calendar.
Medifast's revenue by initial application period cumulative effect transition goes back to fiscal 2018, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.